2. Search Result
Search Result
Results for "

DAPK1

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Peptides

2

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15513
    TC-DAPK 6
    5+ Cited Publications

    		 DAPK Cancer
    TC-DAPK 6 is a potent, ATP-competitive, and highly selective DAPK inhibitor (IC50=69 and 225 nM against DAPK1 and DAPK3, respectively, with 10 μM ATP).
    TC-DAPK 6
  • HY-15847
    HS38
    1 Publications Verification

    		 DAPK Cardiovascular Disease
    HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with Kds of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders [1].
    HS38
  • HY-RS03527
    DAPK1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DAPK1 Human Pre-designed siRNA Set A contains three designed siRNAs for DAPK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DAPK1 Human Pre-designed siRNA Set A
    DAPK1 Human Pre-designed siRNA Set A
  • HY-169109
    DAPK1-IN-1

    		DAPK Neurological Disease
    DAPK1-IN-1 (compound 10) is a death-associated protein kinase 1 (DAPK1) inhibitor with a Kd value of 0.63 μM. DAPK1-IN-1 can be used in Alzheimer’s disease research [1].
    DAPK1-IN-1
  • HY-P5277
    TAT-GluN2BCTM

    		DAPK Neurological Disease
    TAT-GluN2BCTM is a membrane-permeable DAPK1-targeting peptide. TAT-GluN2BCTM targets active DAPK1 to lysosomes for degradation. TAT-GluN2BCTM protects neurons from oxidative stress and NMDAR-mediated excitotoxicity by knocking down DAPK1. TAT-GluN2BCTM can be used in the study of neuroprotection [1].
    TAT-GluN2BCTM
  • HY-131909
    CJ-2360

    		Anaplastic lymphoma kinase (ALK) Cancer
    CJ-2360 is a potent and orally active ALK inhibitor with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated [1].
    CJ-2360

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: